Cell-based Assays Market Size, Share & Trends Analysis By Product & Service, By Type, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
Global cell-based assays market is projected to be worth USD 30.4 billion by 2030
According to SPER Market Research, the cell-based assays market is estimated to reach USD 30.4 billion by 2030 with a CAGR of 7.4%. Rising prevalence of infectious diseases and risk of pandemics has propelled research and development for vaccines and novel drug developments. Cell-based assays are used in drug development processes to improve reliability, efficiency and decrease lead time.
Impact of COVID-19 on the Cell-based Assays Market
COVID-19 has increased the burden on healthcare industry. R&D activities have scaled up to meet the urgent need of vaccines and drugs against COVID-19. The funding and investments in research have also been increased due to which research activities were unaffected in operations during the pandemic. Small and large players of this market are aligning their goals towards research market to tap the opportunities. Thus, manufacturing of cell-based assays is also growing at a significant rate. Cell-based assays provide early detection with more accuracy due to which it is more preferred as compared to other conventional assays.
Scope of the report:
Market size available for years
2019-2030
Base year considered
2021
Forecast period
2022-2030
Segments covered
By Product & Service, By Type, By End User
Geographies covered
North America, Europe, APAC, Latin America and the Middle East & Africa
Companies Covered
AAT Bioquest, Becton, Dickinson and Company, BioAgilytix Labs, Charles River Laboratories, Danaher Corporation, Lonza, Merck KGaA, PerkinElmer, Inc., Promega Corporation, Reaction Biology Corporation, Thermo Fisher Scientific
Driver: Adoption of Cell-based assays for discovery of drugs
The cell-based assays offer many advantages as compared to biochemical assays such as consistent tissue-specific responses, greater efficiency, cost effectiveness and shorter lead time. Therefore, many pharmaceutical and biotechnology companies are adopting cell-based assays in place of biochemical assays for drug discovery. Cell-based assays can be used for lead identification and optimization in drug discovery process.
Restraints: High instrument cost
The technologies of high-throughput screening and high-content screening are highly costly. The cost of these technologies can increase with an increase in the complexity of a molecule to be assayed. Academic institutions can’t afford to own these technologies for research due to budget constraints. In biopharmaceutical companies, cost of production increases significantly due to the adoption of such systems, maintenance charges and indirect costs.
Opportunity: Emerging markets in Asia
Asian countries such as India, China are economically emerging countries which offer significant growth opportunities to cell-based assays market. The labor and raw material cost is comparatively cheaper in these countries. The pandemic risk is also higher due to large population. Moreover, supportive government initiatives, rising focus on life science research and increasing R&D funding also attracts small and large players of cell-based assays market to these countries.
Challenge: Restrictions on reagents usage
There are many factors that restrict the growth of reagents in cell-based assays market. Product end-user license restricts the usage of reagents for specific assays only. In such case, the better reagents available in the market are not adopted even when they are of superior quality. This can pose a challenge to the growth of this market in reagents segment.
Cell-based Assays Market by Product & Service:
Based on product & service, market has been segmented into Consumables (Reagents, Assay Kits [Reporter Gene Assays, Cell Growth Assays, Second Messenger Assays, Cell Death Assays, Other Assay Kits], Cell Lines [Immortalized Cell Lines, Primary Cell Lines, Stem Cell Lines]), Microplates, Probes & Labels, Other Consumables, Instruments & Software, Services
Cell-based Assays Market by Type:
Based on type, the market is segmented into Drug Discovery (Toxicity Studies, Pharmacodynamic Studies, Pharmacokinetic Studies), Basic Research, Other Application
Cell-based Assays Market by End User:
Based on end user, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, CROs, Research & Academic Institutes
Pharmaceutical & Biopharmaceutical companies have the largest share of this market by end user due to high R&D expenditure, increasing number of projects in drug discovery and collaborations & partnerships between companies and
Cell-based Assays Market by Region:
North America owns the largest share of this market owing to supportive government initiatives, rising funding in research, increasing penetration of CRPs and high adoption of advanced technologies.
According to SPER Market Research, the cell-based assays market is estimated to reach USD 30.4 billion by 2030 with a CAGR of 7.4%. Rising prevalence of infectious diseases and risk of pandemics has propelled research and development for vaccines and novel drug developments. Cell-based assays are used in drug development processes to improve reliability, efficiency and decrease lead time.
Impact of COVID-19 on the Cell-based Assays Market
COVID-19 has increased the burden on healthcare industry. R&D activities have scaled up to meet the urgent need of vaccines and drugs against COVID-19. The funding and investments in research have also been increased due to which research activities were unaffected in operations during the pandemic. Small and large players of this market are aligning their goals towards research market to tap the opportunities. Thus, manufacturing of cell-based assays is also growing at a significant rate. Cell-based assays provide early detection with more accuracy due to which it is more preferred as compared to other conventional assays.
Scope of the report:
Market size available for years
2019-2030
Base year considered
2021
Forecast period
2022-2030
Segments covered
By Product & Service, By Type, By End User
Geographies covered
North America, Europe, APAC, Latin America and the Middle East & Africa
Companies Covered
AAT Bioquest, Becton, Dickinson and Company, BioAgilytix Labs, Charles River Laboratories, Danaher Corporation, Lonza, Merck KGaA, PerkinElmer, Inc., Promega Corporation, Reaction Biology Corporation, Thermo Fisher Scientific
Driver: Adoption of Cell-based assays for discovery of drugs
The cell-based assays offer many advantages as compared to biochemical assays such as consistent tissue-specific responses, greater efficiency, cost effectiveness and shorter lead time. Therefore, many pharmaceutical and biotechnology companies are adopting cell-based assays in place of biochemical assays for drug discovery. Cell-based assays can be used for lead identification and optimization in drug discovery process.
Restraints: High instrument cost
The technologies of high-throughput screening and high-content screening are highly costly. The cost of these technologies can increase with an increase in the complexity of a molecule to be assayed. Academic institutions can’t afford to own these technologies for research due to budget constraints. In biopharmaceutical companies, cost of production increases significantly due to the adoption of such systems, maintenance charges and indirect costs.
Opportunity: Emerging markets in Asia
Asian countries such as India, China are economically emerging countries which offer significant growth opportunities to cell-based assays market. The labor and raw material cost is comparatively cheaper in these countries. The pandemic risk is also higher due to large population. Moreover, supportive government initiatives, rising focus on life science research and increasing R&D funding also attracts small and large players of cell-based assays market to these countries.
Challenge: Restrictions on reagents usage
There are many factors that restrict the growth of reagents in cell-based assays market. Product end-user license restricts the usage of reagents for specific assays only. In such case, the better reagents available in the market are not adopted even when they are of superior quality. This can pose a challenge to the growth of this market in reagents segment.
Cell-based Assays Market by Product & Service:
Based on product & service, market has been segmented into Consumables (Reagents, Assay Kits [Reporter Gene Assays, Cell Growth Assays, Second Messenger Assays, Cell Death Assays, Other Assay Kits], Cell Lines [Immortalized Cell Lines, Primary Cell Lines, Stem Cell Lines]), Microplates, Probes & Labels, Other Consumables, Instruments & Software, Services
Cell-based Assays Market by Type:
Based on type, the market is segmented into Drug Discovery (Toxicity Studies, Pharmacodynamic Studies, Pharmacokinetic Studies), Basic Research, Other Application
Cell-based Assays Market by End User:
Based on end user, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, CROs, Research & Academic Institutes
Pharmaceutical & Biopharmaceutical companies have the largest share of this market by end user due to high R&D expenditure, increasing number of projects in drug discovery and collaborations & partnerships between companies and
Cell-based Assays Market by Region:
North America owns the largest share of this market owing to supportive government initiatives, rising funding in research, increasing penetration of CRPs and high adoption of advanced technologies.
1. INTRODUCTION
1.1. Scope of the report
1.2. Market segment analysis
2. RESEARCH METHODOLOGY
2.1. Research data source
2.1.1. Secondary data
2.1.2. Primary data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impact of the Cell-based Assays Market
5. MARKET VARIABLES AND OUTLOOK
5.1. SWOT analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL analysis
5.2.1. Political landscape
5.2.2. Economic landscape
5.2.3. Social landscape
5.2.4. Technological landscape
5.2.5. Environmental landscape
5.2.6. Legal landscape
5.3. PORTER’S five forces analysis
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of Buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat map analysis
6. GLOBAL CELL-BASED ASSAYS MARKET, BY PRODUCT AND SERVICE, 2019-2030 (USD MILLION)
6.1. Consumables
6.1.1. Reagents
6.1.2. Assay Kits
6.1.2.1. Reporter Gene Assays
6.1.2.2. Cell Growth Assays
6.1.2.3. Second Messenger Assays
6.1.2.4. Cell Death Assays
6.1.2.5. Other Assay Kits
6.2. Cell Lines
6.2.1. Immortalized Cell Lines
6.2.2. Primary Cell Lines
6.2.3. Stem Cell Lines
6.3. Microplates
6.4. Probes & Labels
6.5. Other Consumables
6.6. Instruments & Software
6.7. Services
7. GLOBAL CELL-BASED ASSAYS MARKET, BY TYPE, 2019-2030 (USD MILLION)
7.1. Drug Discovery
7.1.1. Toxicity Studies
7.1.2. Pharmacodynamic Studies
7.1.3. Pharmacokinetic Studies
7.2. Basic Research
7.3. Other Application
8. GLOBAL CELL-BASED ASSAYS MARKET, BY END USER, 2019-2030 (USD MILLION)
8.1. Pharmaceutical & Biopharmaceutical Companies
8.2. CROs
8.3. Research & Academic Institutes
9. GLOBAL CELL-BASED ASSAYS MARKET, BY REGION, 2019-2030 (USD MILLION)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. COMPANY PROFILES
10.1. AAT Bioquest
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Becton, Dickinson and Company
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. BioAgilytix Labs
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Charles River Laboratories
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Danaher Corporation
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Lonza
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Merck KGaA
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. PerkinElmer, Inc.
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. Promega Corporation
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Reaction Biology Corporation
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. Thermo Fisher Scientific
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
1.1. Scope of the report
1.2. Market segment analysis
2. RESEARCH METHODOLOGY
2.1. Research data source
2.1.1. Secondary data
2.1.2. Primary data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impact of the Cell-based Assays Market
5. MARKET VARIABLES AND OUTLOOK
5.1. SWOT analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL analysis
5.2.1. Political landscape
5.2.2. Economic landscape
5.2.3. Social landscape
5.2.4. Technological landscape
5.2.5. Environmental landscape
5.2.6. Legal landscape
5.3. PORTER’S five forces analysis
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of Buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat map analysis
6. GLOBAL CELL-BASED ASSAYS MARKET, BY PRODUCT AND SERVICE, 2019-2030 (USD MILLION)
6.1. Consumables
6.1.1. Reagents
6.1.2. Assay Kits
6.1.2.1. Reporter Gene Assays
6.1.2.2. Cell Growth Assays
6.1.2.3. Second Messenger Assays
6.1.2.4. Cell Death Assays
6.1.2.5. Other Assay Kits
6.2. Cell Lines
6.2.1. Immortalized Cell Lines
6.2.2. Primary Cell Lines
6.2.3. Stem Cell Lines
6.3. Microplates
6.4. Probes & Labels
6.5. Other Consumables
6.6. Instruments & Software
6.7. Services
7. GLOBAL CELL-BASED ASSAYS MARKET, BY TYPE, 2019-2030 (USD MILLION)
7.1. Drug Discovery
7.1.1. Toxicity Studies
7.1.2. Pharmacodynamic Studies
7.1.3. Pharmacokinetic Studies
7.2. Basic Research
7.3. Other Application
8. GLOBAL CELL-BASED ASSAYS MARKET, BY END USER, 2019-2030 (USD MILLION)
8.1. Pharmaceutical & Biopharmaceutical Companies
8.2. CROs
8.3. Research & Academic Institutes
9. GLOBAL CELL-BASED ASSAYS MARKET, BY REGION, 2019-2030 (USD MILLION)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. COMPANY PROFILES
10.1. AAT Bioquest
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Becton, Dickinson and Company
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. BioAgilytix Labs
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Charles River Laboratories
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Danaher Corporation
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Lonza
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Merck KGaA
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. PerkinElmer, Inc.
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. Promega Corporation
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Reaction Biology Corporation
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. Thermo Fisher Scientific
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
